Press Releases

Press Releases

Samsung Biologics announces the first contract for its Plant 3 facility

Samsung Biologics announces the first contract for its Plant 3 facility



Incheon, South Korea ? February, 22nd, 2018: Samsung Biologics, headquartered in Incheon, South Korea announced that it has entered into the first manufacturing contract for its Plant 3 facility

According to Samsung Biologics, the approximate value of the contract is 148 million US dollars if the product is successful in the clinic and moves forward with commercial launch.

Samsung Biologics’ Plant 3 facility was mechanically completed last November. It has 180,000 liters total capacity and is expected to be cGMP operational by Q4 2018.

TH Kim, CEO of Samsung Biologics, commented “We are excited to enter into this partnership with a fast growing company and very pleased to be chosen to provide a high quality life-saving product to their patients.”

He also added that “As products from our Plant 1 (6 x 5,000L) and Plant 2 (10 x 15,000L) facilities mature, Plant 3 will be utilized to supply those with increasing demand to ensure that we continue to meet our client’s demand. We continue to discuss with multiple biopharmaceutical companies for long term partnership in Plant 3. As such, the utilization rate in Plant 3 may ramp up more quickly than anticipated.”

 

Samsung Biologics announces the first contract for its Plant 3 facility



Incheon, South Korea – February, 22nd, 2018: Samsung Biologics, headquartered in Incheon, South Korea announced that it has entered into the first manufacturing contract for its Plant 3 facility

According to Samsung Biologics, the approximate value of the contract is 148 million US dollars if the product is successful in the clinic and moves forward with commercial launch.

Samsung Biologics’ Plant 3 facility was mechanically completed last November. It has 180,000 liters total capacity and is expected to be cGMP operational by Q4 2018.

TH Kim, CEO of Samsung Biologics, commented “We are excited to enter into this partnership with a fast growing company and very pleased to be chosen to provide a high quality life-saving product to their patients.”

He also added that “As products from our Plant 1 (6 x 5,000L) and Plant 2 (10 x 15,000L) facilities mature, Plant 3 will be utilized to supply those with increasing demand to ensure that we continue to meet our client’s demand. We continue to discuss with multiple biopharmaceutical companies for long term partnership in Plant 3. As such, the utilization rate in Plant 3 may ramp up more quickly than anticipated.”

 

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION